Stevanato Group S.p.A. (STVN) Stock: Price, Forecast & Analyst Target
Stevanato Group S.p.A. (STVN) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $15.93 (+3.71%), as of the Nov 19, 2026 trading session; market cap $4.35B.
Educational signal · not a buy or sell recommendation · How to read this
Stevanato Group S.p.A. · STVN · NYSE · Healthcare · Medical - Instruments & Supplies
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Stevanato Group S.p.A. (STVN)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth, but a full valuation. Business Quality: Solid; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- EPS beat 0 of the last 4 reports
- Altman Z 3.63 · Piotroski F 5
- ROE 9.3% · ROA 5.5% · current ratio 1.73
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 72 | Strong | |
| 69 | Strong | |
| 74 | Strong | |
| 74 | Strong | |
| 73 | Strong | |
| 73 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $15.93 | |
| Change on the day | +3.71% | |
| 52-week range | $12.05–$24.01 | |
| Market capitalisation | $4.35B | — |
| Price / earnings (trailing) | 27.22 | |
| Shares traded on the day | 492.6K | |
| Beta (volatility vs the S&P 500) | 0.8 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Stevanato Group S.p.A. (STVN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Stevanato Group S.p.A. (STVN), and what does it report?
Short answer
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Stevanato Group S.p.A. (STVN) is listed on NYSE. Healthcare / Medical Instruments & Supplies SEC filing business address: Piombino Dese (PD) VIA Molinella, 17, Padua, 35017. It employs 6,010 people and is led by Franco Stevanato. The market values it at $4.35B.
What do the latest results show for Stevanato Group S.p.A. (STVN)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | €303M | €36M | €0.13 (diluted) |
| Dec 2025 | €346M | €48M | €0.17 (diluted) |
| Mar 2026 | €274M | €28M | €0.10 (diluted) |
| Jun 2026 | €302M | €23M | €0.08 (diluted) |
What are the financial strengths and risks for Stevanato Group S.p.A. (STVN)?
Short answer · as of
The MoonshotScore pillars rate business quality, durable growth as strengths. The distress and quality screens read Altman Z 3.63 · Piotroski F 5. Trailing ratios: ROE 9.3% · ROA 5.5% · current ratio 1.73.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 27.22 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Stevanato Group S.p.A. (STVN)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.25B · EPS 0.60 · 10 analysts. Current published price targets run low $17.50 · high $32.00 · consensus $24.50 · median $24.00 against a quoted price of $15.93 (as of Nov 19, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Stevanato Group S.p.A. compare with its peers?
Short answer
Stevanato Group S.p.A.'s score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Stevanato is a consolidated supplier of critical pharma manufacturing infrastructure, a position earned through manufacturing excellence and regulatory relationships. The company is not a low-cost commodity manufacturer—it competes on quality, compliance, and integrated solutions (vials plus delivery systems plus processing equipment from a single vendor). This integrated model is different from pure vial manufacturers or pure equipment builders.
Compared to peer equipment makers (Bausch + Lomb parent Bausch Health competitors), Stevanato is more exposed to consumable demand cycles. Compared to pure vial suppliers, Stevanato has scale advantages and integrated offerings. Compared to contract manufacturers, Stevanato is upstream in the supply chain, insulated from formulation risk. The real peer set is large-cap pharma suppliers like Sartorius or Getinge, all facing shared cycles around pharma capital spending and biotech activity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $55.45 Nov 18, 2026 | $2.82B | 95 5-pillar Nov 18, 2026 | |
| $64.02 Nov 19, 2026 | $12.7B | 87 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| Stevanato Group S.p.A. (STVN) — this page | $15.93 | $4.35B | 73 |
| $175.76 Nov 19, 2026 | $4.40B | 73 5-pillar Nov 18, 2026 | |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $47.09 Nov 19, 2026 | $1.97B | 64 5-pillar Nov 18, 2026 | |
| $24.13 Nov 19, 2026 | $3.00B | 62 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $20.95 Nov 18, 2026 | $7.49B | 35 5-pillar Nov 18, 2026 | |
| $135.68 Nov 19, 2026 | $7.14B | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $17.50 – $32.00
- Consensus target
- $24.50
- Median target
- $24.00
- Revenue estimate
- $1.25B
- EPS estimate
- $0.60
Consensus record · Captured .
Measured against a quoted price of $15.93 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 9, 2026
- Transactions
- 27
- Identified insiders
- 9
- Purchases
- 2
- Sales
- 8
- Other transactions
- 17
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held STVN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported STVN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Stevanato Group S.p.A. (STVN)?
What Investors Ask About Stevanato Group S.p.A. (STVN) — Healthcare
These answers are editorial: 1 of these 9 answers is drawn from the STVN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for STVN?
STVN carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Stevanato Group S.p.A. provides integrated solutions for the pharmaceutical and healthcare industries.
Is STVN a good stock to buy?
Stock Expert AI does not rate STVN buy, sell or hold. Stevanato Group S.p.A. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the STVN stock price today?
The last price recorded for Stevanato Group S.p.A. (STVN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the STVN price target?
The analyst consensus price target for Stevanato Group S.p.A. (STVN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for STVN?
Stevanato Group S.p.A. faces several risks inherent to the medical instruments and supplies industry. Economic downturns and reduced healthcare spending could negatively impact demand for its products and services.
What are the key factors to evaluate for STVN?
Stevanato Group S.p.A. (STVN) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. By establishing a presence in these markets, Stevanato Group can tap into new customer bases and diversify its revenue streams. Not financial advice.
How frequently does STVN data refresh on this page?
STVN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven STVN's recent stock price performance?
Stevanato Group S.p.A. (STVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in the pharmaceutical and healthcare industries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STVN overvalued or undervalued right now?
The trailing P/E of Stevanato Group S.p.A. (STVN) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 5 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com